TBWA wins three global Merck brands

Share this article:

Merck KGaA has tapped TBWA on three of its consumer healthcare brands: Nasivin, Femibion and Flexagil.

TBWA will handle global communication strategies for each of the brands. The campaigns will debut globally in 2009, according to a company statement.

Neither company responded to inquiries about the assignment. In the statement, Hubertus von Lobenstein, CEO TBWA\Group Germany, said of the wins: “It shows the value of a great team, the international experience as well as the power of our fundamental idea: Disruption.”

Merck's global operating activities function under the umbrella Merck KGaA of Germany, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%, according to the statement. Merck & Co., the US subsidiary, became an independent company in 1917.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...